A Standardisation Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real World Populations in Psoriasis.

Title : A Standardisation Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real World Populations in Psoriasis

Source : PubMed
ID : 30822358
Authors : Yiu, Z. Z. N.; Mason, K. J.; Barker, J. N. W. N.; Hampton, P. J.; McElhone, K.; Smith, C. H.; Warren, R. B.; Griffiths, C. E. M.; Lunt, M.; Burden, A. D
Year : 2019
Disease Category : Skin diseases
Focused Population : Not Specified
Priori/Posteriori : Posteriori
Single-study Generalibility? : Multiple
Score/Non-Score : Non-score
Tutorial/Method : Propensity score and propensity score-based method
Compared general demographic and patient characteristics : Yes
Compared disease-specific clinical characteristics : Yes
Compared adverse events : Yes
Compared outcomes/treatment effect (including survival) : No
Trial participants vs. general population (from EHR, survey, a cohort, etc) : Yes
Use propensity score : Yes
Real-world data sources : BADBIR is a prospective pharmacovigilance registry of psoriasis patients that was established in 2007 in the UK and Ireland
Target Population Data Type Levels : International